Accelerate to discover

Back to filter

Related topics

Webinar: Join us for an In-Depth Look at the Revolutionary Small Animal Radiotherapy System at STTARR

Precision X-Ray

Aug 17, 2023

Register for an engaging webinar led by Naz Chaudary, Ph.D., and Research Technician, Alex Wang from the...

Optimizing Gene Expression with Bioluminescence & the piggyBac System

Spectral Instruments Imaging

Aug 15, 2023

Discover how bioluminescence imaging & the piggyBac gene editing system optimize & track gene expression in mouse...

High-plex immunofluorescence imaging and traditional histology of the same tissue section

RareCyte

Aug 7, 2023

RareCyte Orion’ platform has been used for collecting H&E and high-plex immunofluorescence images from the same cells...

Drive key insights and discoveries with NEW Live Cell Analysis applications for eSight system

Agilent technologies

Aug 2, 2023

eSight is now powerful like never before. Learn more about new dedicated application modules for live-cell analysis: 3D...

Sep 30, 2023

Single cell-resolution in situ sequencing elucidates spatial dynamics of multiple sclerosis

Vizgen

Jul 14, 2023

MERFISH integrates spatial transcriptomics technology with high resolution spatial imaging, fluidics, image processing,...

High speed, compact and fully automated microscope inside your incubator? Lumascope850

Etaluma

Jul 13, 2023

The powerful, new LS850 Microscope is the latest generation of our fully automated three-channel flagship model and...

MARS - High Efficiency Separation of CD34+ HSC from Mobilized Blood

Applied Cells

Jul 12, 2023

MARS platform provides an easy and cost-effective protocol for CD34+ cell isolation. Single pass CD34+ HSC enrichment...

Sep 30, 2023

InAlyzer - The technology chosen by NASA

MEDIKORS

Jul 10, 2023

MEDIKORS's InAlyzer was finally selected as the equipment to be used for NASA's space environment biological research

Show all topics (10)

Preclinical cardiac safety assesment

Mar 22, 2016

Over the last two decades, a number of blockbuster drugs have been withdrawn or have incurred safety warnings by regulatory agencies due to adverse cardiac effects. In addition, lead compounds or drug candidates are frequently terminated at late stages of drug development due to cardiac safety concerns. Both of these factors can significantly impact the overall cost of drug discovery; consequently, pharmaceutical companies and regulatory agencies have implemented procedures to address these issues.

Most, if not all, in vitro assay systems for cardiac safety are designed to screen for surrogates of arrhythmia, such as hERG channel interaction, rather than arrhythmia itself. Assays designed to screen for compounds that may affect repolarization and induce arrhythmia in the context of the whole heart or heart tissue are not implemented until much later in drug development. These include sophisticated, technically demanding, lowthroughput, and costly procedures such as the Purkinje fiber assay, ventricular wedge assay, and the Langendorff whole heart assay, or telemetry experiments in live and anesthetized animals. The field of preclinical cardiac safety can certainly benefit from an assay system that allows for integrated assessment of compound action on ion channel and non-ion channel targets involved in cardiac excitation-contraction coupling.

The RTCA Cardio Instrument in conjunction with iCell Cardiomyocytes comprises an assay system providing integrated assessment of compound action on multiple targets involved in heart function. This assay system can sensitively and quantitatively detect the effect of compounds on the major ion channels involved in heart function, namely calcium, sodium, and potassium channels. Another major advantage of the assay system is the time resolution. The RTCA Cardio Instrument has a data acquisition rate of 12.5 ms per well of a 96-well plate and can be used simultaneously to monitor acute and chronic drug effects up to days and weeks. The utility of the time-dependent monitoring of compound action on cardiomyocytes can be demonstrated by testing compounds that acutely and directly block hERG channels (E4031, cisapride, etc.) and compounds that interfere with protein trafficking (pentamidine) in a sub-chronic manner. The RTCA Cardio Instrument is able to detect the effects of these compounds on the beating rate and duration of iCell Cardiomyocytes.

The xCELLigence System RTCA Cardio Instrument, in conjunction with iCell Cardiomyocytes, represents a physiologically relevant and predictive assay system for preclinical cardio-safety assessment of lead compounds. The features of this assay system, including time resolution, dynamic monitoring of mechanical beating activity of cardiomyocytes, and 96-well throughput, will surely provide additional mechanistic and toxicity information for compound action on the heart.

Application
Product news

Related technologies: Real-time, label free cell analysis

Brand profile

Agilent technologies

Agilent provides xCELLigence impedance-based, label-free, real time cell analysis system and NovoCyte flow cytometers.

Related products

Cardio Instrument is a high-resolution system for label-free-dual-mode monitoring of cardiomyocyte and cardiotoxicity testing

show detail

The new CardioECR system combines impedance and Multi Electrode Array (MEA) technology with a pacing function

show detail

We supply and support Life-Science Technologies in the territory of Central and Eastern Europe.

Czech Republic

Slovakia

Hungary

Poland

Croatia

Slovenia

Serbia

Romania

Bulgaria

Latvia

Lithuania

Estonia

Russia

Ukraine

Belarus

Turkey